Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Accumulating data suggest that α7 nicotinic acetylcholine receptors (α7nAChRs) are an important therapeutic target for the treatment of Alzheimer’s disease (AD) and schizophrenia. The homopentameric ligand-gated ion channel α7nAChR consists of five identical α7 subunits that are encoded by the CHRNA7 (cholinergic receptor nicotinic alpha7 subunit) gene. Moreover, α7nAChRs are densely distributed throughout the hippocampus, cortex, and thalamus brain regions, but sparsely in the striatum, forebrain, and medulla. Compared with other nAChRs, α7nAChR binds with low affinity to the naturally occurring neurotransmitter acetylcholine and the non-specific exogenous agonist nicotine, and with high affinity to the specific antagonists α-bungarotoxin and methyllycaconitine. Reports indicate that α7nAChR plays important roles in neurotransmitter release, cognitive functioning, and the cholinergic anti-inflammatory response. Genetic variations that alter CHRNA7 mRNA and protein expression or cause α7nAChR dysfunction are associated with many brain disorders. Our previous studies revealed that α7nAChR exerts neuroprotection in AD by acting as a cargo receptor for binding the autophagosomal marker protein LC3 and engulfing extracellular neurotoxic Aβ1–42 during autophagic degradation of the α7nAChR-Aβ1–42 complex. However, the role of α7nAChRs in other diseases remains unknown. Here, we review and summarize the essential characteristics and current findings concerning α7nAChRs in four common brain diseases (AD, Parkinson’s disease, schizophrenia, and depression), which may elucidate the role of α7nAChRs and inform innovative research and novel treatments that target α7nAChRs in brain disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The Trier Social Stress Test (TSST) is regarded as the gold standard in simulating a stressful social situation”
From Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665 · cited 1×
“Next-generation sequencing (NGS) data of RNA sequencing reveal the presence and quantity of CHRNA7 RNA in 27 human tissues and show that the top eight tissues that express CHNRA7 mRNA are the adrenal, small intestine, testis, stomach, duodenum, thyroid, colon, and brain [19].”
BackgroundSELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“Loss of cholinergic tone and acetylcholine levels in the brain are thought to be responsible for the gradual cognitive decline in AD patients [34].”
BackgroundNicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228 · cited 1×
“The expression of α7nAChRs in the immune system is of particular interest, as this system plays a crucial role in regulating the cholinergic anti-inflammatory pathway [13].”
Background2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059 · cited 1×
“LC3 is an autophagosomal marker protein that is necessary for autophagosomal membrane formation [47].”
BackgroundLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821 · cited 1×
“One clinical study has suggested that levodopa either slows the progression of PD or has a prolonged effect on the symptoms of the disease, although the neuroimaging data indicate that levodopa may accelerate the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine trans…”
BackgroundLinkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 2×
“Inheritance of a defect in attentional disturbances in schizophrenia (a decrease in the normal inhibition of the P50 (50-millisecond latency) auditory-evoked response to the second of paired stimuli), is thought to be associated with DNA variants of the CHRNA7 gene [84].”
Background
Research works printed but not linked: 1
- Carlson A.B. Kraus G.P. Physiology, Cholinergic Receptors StatPearls Treasure Island, FL, USA 2022 30252390
Cited by
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 51
Angelova, V. T., GEORGIEV, B., Pencheva, T., Pajeva, I. K., Rangelov, M. A., Todorova, N. H., Zheleva‐Dimitrova, D., Kalcheva-Yovkova, E., Valkova, I., Vassilev, N. G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16091194 · Cited by 35
“Donepezil is a selective, noncompetitive, and rapidly reversible inhibitor [11]; galanthamine acts as a reversible and competitive acetylcholinesterase inhibitor that also up-regulates the expression of nicotinic receptors [12]; rivastigmine is pseudo-irreversible and also inhibits BChE [7,13].”
Nagori, K., Pradhan, M., & Nakhate, K. T. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150925 · Cited by 27
Kumar, S., Akhila, P. V., & Suchiang, K. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.10.408 · Cited by 28
Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
Sánchez, J. D., Alcántara, A. R., González, J. F., & Sánchez-Montero, J. M. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2264766 · Cited by 26
Targeting the cholinergic anti-inflammatory pathway: an innovative strategy for treating diseases
Li, Y., Ding, S., & Wang, Y. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10288-7 · Cited by 30
Zhang, Y., Ma, R., Wang, W., Deng, Q., Cao, C., Yu, C., Li, S., Shi, L., & Tian, J. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112139 · Cited by 23
Nebrisi, E. E., Lozon, Y., & Öz, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073210 · Cited by 24
Nicotinic receptors in airway disease
Borkar, N. A., Thompson, M. A., Bartman, C. M., Khalfaoui, L., Sine, S. M., Sathish, V., Prakash, Y. S., & Pabelick, C. M. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00268.2023 · Cited by 21
RETRACTED: Recent advances in nicotine electrochemical biosensors: A review
Mirani, A., Kianfar, E., Maleknia, L., & Javanbakht, M. (2024) · Case Studies in Chemical and Environmental Engineering · doi:10.1016/j.cscee.2024.100753 · Cited by 19
RetractedAvstrikova, M., Rodríguez, P. M., Burke, S. M., Hibbs, R. E., Changeux, J., & Cecchini, M. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2420993122 · Cited by 19
“Furthermore, α 7 - nAChR dysfunction is implicated in a variety of neurological disorders including Alzheimer’s disease ( 10 , 11 ), Parkinson’s disease ( 12 ), schizophrenia ( 13 ), and depression ( 14 ).”
Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
Garcia‐Ratés, S., García‐Ayllón, M., Falgàs, N., Brangman, S. A., Esiri, M. M., Coen, C. W., & Greenfield, S. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13869 · Cited by 15
Neuronal and Glial α7 Nicotinic Acetylcholine Receptors: Role in Alzheimer’s Disease Pathophysiology
Rennie, K. (2025) · Life · doi:10.3390/life15071032 · Cited by 14
“A number of properties distinguish the homomeric α 7nAChR from other nAChR subtypes, including relatively low affinity for ACh and nicotine, short open time, rapid and long-lasting desensitization, and high permeability to Ca 2+ [25,26].”
Ranglani, S., Hasan, S., Komorowska, J., Medina, N. M., Mahfooz, K., Ashton, A., Garcia‐Ratés, S., & Greenfield, S. A. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04079-7 · Cited by 11
Liu, J., Liu, M., Shi, S., Jiang, F., Zhang, Y., Guo, J., & Gong, X. (2024) · PAIN Reports · doi:10.1097/pr9.0000000000001163 · Cited by 11
“32 In addition, we previously reported that tropisetron reduces inflammation and myocardial ischemic–reperfusion injury after heart valve replacement surgery.”
Backgroundα7 nicotinic acetylcholine receptors regulate radial glia fate in the developing human cortex
Mukhtar, T., Siebert, C., Wang, Y. J., Pebworth, M.-P., White, M. L., Wu, T., Huang, T., Zuo, G., Ross, J. M., Baltazar, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61167-5 · Cited by 11
“Despite the importance of nAChRs in human cognition and disease 27,28,31,32 , the expression and roles of CHRNA7 and CHRFAM7A during human cortical development are not well understood.”
Abraham, S. M., Suresh, S., & Komal, P. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01586-6 · Cited by 10
Kuo, P., Chen, L., Li, S., Chen, Z.-R., & Chen, J. (2025) · Antioxidants · doi:10.3390/antiox14040413 · Cited by 7
He, Y., Polymeropoulos, C. M., Mohrman, M. A., Truslow, S. O., Xiao, C., Wu, Y., Birznieks, G., & Polymeropoulos, M. H. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.84 · Cited by 5
“These data support the hypothesis of the effect of mask wearing on treatment response, but the limited sample size in this subset population is a limitation on the analysis. α 7-nAChR features rapid desensitisation during the activation cycle, to prevent excess calcium from entering the cells.”
Nagori, K., Pradhan, M., & Nakhate, K. T. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100619 · Cited by 5
Hamdollahi, M., Asle‐Rousta, M., & Mahmazi, S. (2025) · Biological Trace Element Research · doi:10.1007/s12011-025-04807-7 · Cited by 6
New Multitarget Molecules Derived from Caffeine as Potentiators of the Cholinergic System
Munafó, J. P., Biscussi, B., Obiol, D. J., Costabel, M. D., Bouzat, C., Murray, A. P., & Antollini, S. S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00710 · Cited by 6
Jackson, D. C., Burgon, R. M., Thompson, S., & Sudweeks, S. N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301592 · Cited by 5
Shan, H., Wang, N., Gao, X., Wang, Z., Yu, J., Zhangsun, D., Zhu, X., & Luo, S. (2024) · Marine Drugs · doi:10.3390/md22050200 · Cited by 5
Synchronous activation of striatal cholinergic interneurons induces local serotonin release
Matityahu, L., Hobel, Z. B., Berkowitz, N., Malgady, J. M., Gilin, N., Plotkin, J. L., & Goldberg, J. A. (2026) · Nature Communications · doi:10.1038/s41467-026-70359-6 · Cited by 6
Autism and α7-nicotinic acetylcholine receptors: new pharmacological and herbal interventions
Khattab, N. A., El-Kadem, A. H., Ashour, N. A., El‐Mahdy, N. A., & El‐Shitany, N. A. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00843-1 · Cited by 3
“…the CHRNA7 gene, which encodes the α7nAChR, are linked to a range of neurodevelopmental problems, including ASD potential metabotropic activities of this ionotropic receptor [43]. α7-selective type II positive modulators can disrupt the desensitized state and facilitate the opening of ion channels.”
InfluentialCholine alphoscerate: insights between acquired certainties and future perspectives
Biggio, G., & Mencacci, C. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1613566 · Cited by 4
“Thus, treatments that improve cholinergic function are crucial for the management of symptoms in patients with Alzheimer’s disease (Hampel et al., 2018; Chaudhary et al., 2022; Lee and Hung, 2022).”
Lewandowska, M., Różycka, A., Grzelak, T., Kempisty, B., Jagodziński, P. P., Lianeri, M., & Dorszewska, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041634 · Cited by 2
“We did not observe significant differences in the Mem group in comparison to the water group in all three brain regions, though we noted a trend to reduced α 7 nAChR protein level ( p = 0.054).”
InfluentialAzadi, M. H., Pazooki, P., Ajdary, S., & Shafaroodi, H. (2025) · Cancer Reports · doi:10.1002/cnr2.70387 · Cited by 5
Sun, S. (2024) · American Journal of Translational Research · doi:10.62347/mcpd8618 · Cited by 2
Hameed, E. R., Hameed, M. R., & Obeed, B. N. (2025) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v9i1.1937 · Cited by 1
Tae, H., Ortells, M. O., Ciocarlan, A. G., Aricu, A. N., Lungu, L., Blaja, S., Adams, D. J., & Arias, H. R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00862 · Cited by 1
Kaiser, J., Gertzen, C. G. W., Mann, D., Sachse, C., & Gohlke, P. D. H. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02384 · Cited by 1
Rocha, F. S., Cardoso, R. R., Prado, J. P., Zavan, B., Caixeta, E. S., dos Santos, R. S., de Souza, I. F. F., Nunes-Silva, A., Romero, T. R. L., Barchuk, A. R., et al. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag003 · Cited by 1
Genetic components of microdeletion syndromes and their role in determining schizophrenia traits
Biswal, S. R., Kumar, A., Muthuswamy, S., & Kumar, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09731-y · Cited by 2
“Ca 2 + influx and neurotrans - mitter release occur when the homopentameric ɑ7 receptor is activated [25].”
Tzartos, J. S., Karagiorgou, K., Pechlivanidou, M., Tzartos, S. J., Dudeck, L., Meyer-Lotz, G., Guest, P. C., & Steiner, J. H. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.03.019
Kundu, D., Acharya, S., Wang, S., Cao, Y., Kim, H. J., Cheong, J. H., & Kim, K. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16271
“K + , and Ca 2 + (Lee & Hung, 2022; Vijayaraghavan et al., 1992 ).”
Baldwin, D. S., & Huneke, N. T. M. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.10368
Ma, R., Zhang, Y., Wang, W., Deng, Q., Cao, C., Li, S., Shi, L., Yu, C., Yinhua, Y., & Tian, J. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.106064
Hu, Q., sup, C. Y. S., Xu, Y., Chen, J., Luo, X., & Cong, E. (2025) · Tobacco Induced Diseases · doi:10.18332/tid/209615
“Acetylcholine is an important neurotransmitter involved in the regulation of mood, cognition, and memory functions, and there may be dysfunctions in the acetylcholine system in patients with bipolar disorder 24 .”
The green antidote: phytochemical defense as a natural shield against chemical warfare
Zakaria, N., Ali, M. G., & Zhou, Z. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10189-4
“Galantamine, an alkaloid from Galanthus species, acts as a reversible acetylcholinesterase (AChE) inhibitor and protects neurons by modulating nicotinic receptors (Golime et al. 2018; Lee and Hung 2022; Moreira et al. 2022; Aldubayan et al. 2024).”
Shi, R., Li, Y., Mou, L., Zheng, Y., Xia, L., Liu, Y., Стойка, Р. С., Attila Gabor, S. I. K., Liu, K., & Jin, M. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157813
Multitarget pharmacological effects of Lawsone in mitigating Alzheimer's disease
Bashir, M. A., Ullah, I., Aara, G., Khan, A., & Shah, S. U. A. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178920
Sun, W., Fh, P., Hu, Y., Zhang, M., Ma, W., & Li, S. (2026) · Aquatic Toxicology · doi:10.1016/j.aquatox.2026.107959
Molecular mechanisms of nicotinic acetylcholine receptors in mood dysregulation
Murthy, M. K., & Samal, D. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111880
Zhang, Y., Li, Z., Nie, R., Wu, H., Li, J., Cai, X., Zhang, Y., Lin, X., Duan, R., Liu, S., et al. (2026) · Targetome · doi:10.48130/targetome-0026-0042 · Cited by 1
Roshani, S., Barış, E., Hamurtekin, E., Özoğul, C., & Boşnak, A. S. (2026) · Biomedicines · doi:10.3390/biomedicines14102271
Luo, J., Ping, J., Zhang, Y., Zhu, J., Li, R., Huo, J., Zheng, S., Wan, J., Hu, J., Ye, L., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117543
Sun, J., Gao, G., Wang, S., Li, S., Tang, J., Liu, H., & Tang, T.-S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02776-4
“206 Therefore, modulating the neurotoxic effects of A β through pharmacological intervention or agonistic modulation of the nAChR-A β interaction represents a potential therapeutic approach for AD.”
Metadata
- Authors
- Lee, C.-H., & Hung, S.-Y.
- Affiliations
- Kaohsiung Medical University (TW)
- China Medical University (TW)
- Corresponding author
- Hung, Shih-Ya
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-12-22
- Volume
- 15
- Issue
- 1
- Pages
- 31
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9865019
- OpenAlex
- W4312117327
- Cited by
- 50
- References
- 94
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 12 · 2023: 5
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- the Ministry of Science and Technology of Taiwan (MOST 111-2320-B-039-044-MY3, MOST 110-2811-B-039-509, CMU109-S-28)
- China Medical University (MOST 111-2320-B-039-044-MY3, MOST 110-2811-B-039-509, CMU109-S-28)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha7 nicotinic acetylcholine receptor, CHRNA7, Alzheimer's disease, schizophrenia, Parkinson's disease, depression, autophagy, amyloid-beta clearance, neuroprotection, neurotransmitter release, cognitive function, ligand-gated ion channels, alpha-bungarotoxin, methyllycaconitine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.